paediatrics Brussels 17

Conclusions

• Omission of radiotherapy in Group II and Group III rhabdomyosarcoma results in higher local failure and in some sites can impact on survival • Current trials in North America and Europe are looking at dose escalation up to 59.4 Gy for children with high risk for local failure • It is unclear whether radiotherapy to metastatic sites improve overall outcome of patients